Pacira BioSciences Faces Governance Overhaul Amid Shareholder Activism and Leadership Criticism

### Governance Strain at Pacira BioSciences: A Call for Change

Concerns regarding corporate governance at Pacira BioSciences arise as DOMA Perpetual Capital Management LLC, a significant shareholder, expresses dissatisfaction with the company’s performance under the leadership of CEO Frank Lee. Amid a concerning trajectory, shares of Pacira have plummeted by 56% over the past decade, with a staggering 30% decline observed since Lee took charge. This drop in value, alongside consistent earnings misses and lowered financial forecasts, paradoxically correlates with increased company expenses and executive compensation, leading to heightened shareholder frustration. DOMA, which holds approximately 7.3% of Pacira’s outstanding shares, views these management deficiencies as reflective of a broader issue in corporate governance, prompting them to take action.

In response to these issues, DOMA has nominated three candidates—Christopher Dennis, Oliver Benton Curtis III, and Eric de Armas—for election to Pacira's Board of Directors. Their extensive backgrounds in financial and legal sectors are positioned as assets crucial for addressing the current leadership's perceived shortcomings. DOMA asserts that these fresh perspectives can drive accountability and reinvigorate strategies aligned with shareholder interests. This nomination comes as part of a strategic initiative to halt the erosion of shareholder value, indicating that DOMA is not merely a passive stakeholder but rather an active participant in facilitating change within Pacira’s corporate structure.

As external pressures mount, including broader market challenges, the spotlight shines on how Pacira and its board will respond to these developments. DOMA’s actions underline the increasing trend of shareholder activism in the biotechnology sector, calling for a reevaluation of management and decision-making frameworks. Stakeholders are watching closely, as these changes could have significant implications for Pacira's operational effectiveness and financial health moving forward. The firm's discontent highlights a pivotal moment for Pacira BioSciences, underscoring the necessity for transparency and improved governance to regain investor confidence.

In addition to DOMA’s nominations, the discourse surrounding Pacira's governance also emphasizes the urgent need for management to address ongoing operational challenges. Increasing scrutiny over intellectual property disputes further complicates the company’s landscape, suggesting that a proactive approach to these vulnerabilities is essential. As the company navigates this tumultuous period, the imperative for robust governance and accountability becomes increasingly paramount for securing future success in a highly competitive biotech environment.

The evolving relationship between DOMA Perpetual and Pacira BioSciences reflects a broader narrative within the industry: the tension between growing shareholder demands and management accountability. It signals a critical juncture for Pacira not just in its governance but in reaffirming its commitment to creating long-term value for all stakeholders as it continues to evolve within the complex biotechnology landscape.